1. Home
  2. ECVT vs AUPH Comparison

ECVT vs AUPH Comparison

Compare ECVT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ecovyst Inc.

ECVT

Ecovyst Inc.

HOLD

Current Price

$11.35

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$14.16

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECVT
AUPH
Founded
1935
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
ECVT
AUPH
Price
$11.35
$14.16
Analyst Decision
Strong Buy
Buy
Analyst Count
5
4
Target Price
$12.60
$17.25
AVG Volume (30 Days)
1.4M
784.5K
Earning Date
05-29-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5075.00
EPS
N/A
2.07
Revenue
$723,515,000.00
$283,055,000.00
Revenue This Year
$6.38
$17.79
Revenue Next Year
$6.78
$15.50
P/E Ratio
N/A
$6.80
Revenue Growth
2.70
20.38
52 Week Low
$5.24
$6.83
52 Week High
$12.33
$16.54

Technical Indicators

Market Signals
Indicator
ECVT
AUPH
Relative Strength Index (RSI) 54.74 41.76
Support Level $8.04 $11.05
Resistance Level $11.85 $16.28
Average True Range (ATR) 0.40 0.48
MACD -0.07 -0.01
Stochastic Oscillator 30.00 43.49

Price Performance

Historical Comparison
ECVT
AUPH

About ECVT Ecovyst Inc.

Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: Ecoservices and Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: